Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study
作者： Pasi A. Jänne , Sarada Gurubhagavatula , Beow Y. Yeap , Joan Lucca , Patricia Ostler
DOI: 10.1016/J.LUNGCAN.2003.12.014
关键词:
摘要: … , gefitinib, is an orally active small molecule inhibitor of EGFR. Anti-tumor activity of gefitinib … Both studies demonstrated that there was no additional therapeutic benefit to gefitinib being …
elsevier.com
sci-hub.se 参考文章(25)
Mark M. Moasser, Steven D. Averbuch, Neal Rosen, Andrea Basso, The Tyrosine Kinase Inhibitor ZD1839 ("Iressa") Inhibits HER2-driven Signaling and Suppresses the Growth of HER2-overexpressing Tumor Cells Cancer Research. ,vol. 61, pp. 7184- 7188 ,(2001)
V. Rusch, Ethan Dmitrovsky, C. Cordon-Cardo, S. Hoda, M. Zaman, Jonathan M Kurie, J. Mcintosh, J. Baselga, J. Orazem, Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung Cancer Research. ,vol. 53, pp. 2379- 2385 ,(1993)
Frank V. Fossella, Russell DeVore, Ronald N. Kerr, Jeffrey Crawford, Ronald R. Natale, Frank Dunphy, Leonard Kalman, Vincent Miller, Jin Soo Lee, Melvin Moore, David Gandara, Daniel Karp, Everett Vokes, Mark Kris, Yong Kim, Francis Gamza, Luz Hammershaimb, , Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Journal of Clinical Oncology. ,vol. 18, pp. 2354- 2362 ,(2000) , 10.1200/JCO.2000.18.12.2354
M K Ferguson, C Skosey, P C Hoffman, H M Golomb, Sex-associated differences in presentation and survival in patients with lung cancer. Journal of Clinical Oncology. ,vol. 8, pp. 1402- 1407 ,(1990) , 10.1200/JCO.1990.8.8.1402
K S Albain, J J Crowley, M LeBlanc, R B Livingston, Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. Journal of Clinical Oncology. ,vol. 9, pp. 1618- 1626 ,(1991) , 10.1200/JCO.1991.9.9.1618
Karen Kelly, John Crowley, Paul A. Bunn, Cary A. Presant, Patra K. Grevstad, Carol M. Moinpour, Scott D. Ramsey, Antoinette J. Wozniak, Geoffrey R. Weiss, Dennis F. Moore, Valerie K. Israel, Robert B. Livingston, David R. Gandara, Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial Journal of Clinical Oncology. ,vol. 19, pp. 3210- 3218 ,(2001) , 10.1200/JCO.2001.19.13.3210
J.R. Bignall, Marjorie Martin, SURVIVAL EXPERIENCE OF WOMEN WITH BRONCHIAL CARCINOMA The Lancet. ,vol. 300, pp. 60- 62 ,(1972) , 10.1016/S0140-6736(72)91551-6
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
J.R Woodburn, The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacology & Therapeutics. ,vol. 82, pp. 241- 250 ,(1999) , 10.1016/S0163-7258(98)00045-X
David H. Harpole, James E. Herndon, W. Glenn Young, Walter G. Wolfe, David C. Sabiston, Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence Cancer. ,vol. 76, pp. 787- 796 ,(1995) , 10.1002/1097-0142(19950901)76:5<787::AID-CNCR2820760512>3.0.CO;2-Q